Shree Ganesh Remedies Limited (BOM:540737)
India · Delayed Price · Currency is INR 513.15
+10.15 (2.02%)
At close: Feb 12, 2026
Shree Ganesh Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,005 | 1,086 | 1,259 | 902.2 | 712.88 | 490.82 |
Other Revenue | - | - | - | - | -0 | - |
| 1,005 | 1,086 | 1,259 | 902.2 | 712.88 | 490.82 | |
Revenue Growth (YoY) | -17.57% | -13.74% | 39.54% | 26.56% | 45.24% | -24.22% |
Cost of Revenue | 367.62 | 391.39 | 582.44 | 476.45 | 373.11 | 222.11 |
Gross Profit | 637.6 | 694.57 | 676.52 | 425.74 | 339.77 | 268.71 |
Selling, General & Admin | 128.24 | 117.27 | 97.65 | 69.93 | 48.46 | 73.08 |
Other Operating Expenses | 162.17 | 173.22 | 154.65 | 115.67 | 107.22 | 55.76 |
Operating Expenses | 391.4 | 386.16 | 313.39 | 220.97 | 189.05 | 156.1 |
Operating Income | 246.19 | 308.41 | 363.12 | 204.78 | 150.72 | 112.61 |
Interest Expense | -35.57 | -20.13 | -5.45 | -0.45 | -1.05 | -0.3 |
Interest & Investment Income | 0.19 | 0.19 | 0.65 | 1.35 | 4.17 | 2.66 |
Currency Exchange Gain (Loss) | 17.44 | 17.44 | 21.46 | 23.34 | 26.58 | 9.64 |
Other Non Operating Income (Expenses) | 4.7 | -0.94 | -0.62 | -0.71 | -0.36 | -0.33 |
EBT Excluding Unusual Items | 232.95 | 304.97 | 379.15 | 228.3 | 180.05 | 124.29 |
Impairment of Goodwill | - | - | - | -1.88 | - | - |
Gain (Loss) on Sale of Investments | 7.7 | 7.7 | 2.45 | - | - | 5.22 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | - | 0.19 | - | -0.01 |
Asset Writedown | - | - | - | -0.77 | - | - |
Pretax Income | 240.66 | 312.68 | 381.6 | 225.84 | 180.05 | 129.5 |
Income Tax Expense | 59.84 | 81.99 | 100.52 | 55.64 | 46.07 | 31.95 |
Net Income | 180.82 | 230.68 | 281.08 | 170.2 | 133.99 | 97.54 |
Net Income to Common | 180.82 | 230.68 | 281.08 | 170.2 | 133.99 | 97.54 |
Net Income Growth | -36.49% | -17.93% | 65.14% | 27.03% | 37.36% | -6.84% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 12 | 12 | 12 |
Shares Change (YoY) | 0.09% | 2.08% | 2.49% | 0.42% | 1.82% | -0.01% |
EPS (Basic) | 14.08 | 17.96 | 22.34 | 13.86 | 10.96 | 8.12 |
EPS (Diluted) | 14.08 | 17.96 | 22.34 | 13.86 | 10.96 | 8.12 |
EPS Growth | -36.54% | -19.60% | 61.17% | 26.47% | 34.91% | -6.83% |
Free Cash Flow | - | 74.69 | -6.9 | -345.72 | -19.11 | 33.03 |
Free Cash Flow Per Share | - | 5.82 | -0.55 | -28.16 | -1.56 | 2.75 |
Dividend Per Share | - | - | - | 0.500 | 0.500 | 1.458 |
Dividend Growth | - | - | - | - | -65.71% | 30.12% |
Gross Margin | 63.43% | 63.96% | 53.74% | 47.19% | 47.66% | 54.75% |
Operating Margin | 24.49% | 28.40% | 28.84% | 22.70% | 21.14% | 22.94% |
Profit Margin | 17.99% | 21.24% | 22.33% | 18.87% | 18.80% | 19.87% |
Free Cash Flow Margin | - | 6.88% | -0.55% | -38.32% | -2.68% | 6.73% |
EBITDA | 363.38 | 399.26 | 418.85 | 240.76 | 184.71 | 140.48 |
EBITDA Margin | 36.15% | 36.77% | 33.27% | 26.69% | 25.91% | 28.62% |
D&A For EBITDA | 117.19 | 90.85 | 55.73 | 35.98 | 33.99 | 27.87 |
EBIT | 246.19 | 308.41 | 363.12 | 204.78 | 150.72 | 112.61 |
EBIT Margin | 24.49% | 28.40% | 28.84% | 22.70% | 21.14% | 22.94% |
Effective Tax Rate | 24.87% | 26.22% | 26.34% | 24.64% | 25.59% | 24.68% |
Revenue as Reported | 1,048 | 1,123 | 1,290 | 933.84 | 748.56 | 511.77 |
Advertising Expenses | - | 16.08 | 13.59 | 10.6 | 0.52 | 0.93 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.